Kondro, Wayne
March 2009
CMAJ: Canadian Medical Association Journal;3/3/2009, Vol. 180 Issue 5, p506
Academic Journal
The article offers news briefs concerning the health care industry. The U.S. government has allowed the pharmaceutical industry to distribute medical journal articles to physicians to promote the off-label use of their drugs. CV Technologies has launched COLD-FX as the treatment for cold and flu for the 2010 Olympic and Paralympic Winter Games in Vancouver, British Columbia. Angiotensin-Converting Enzyme (ACE) inhibitors and angiotensin II are prohibited among high blood patients.


Related Articles

  • Washington Insider. PITTS, PETER // Medical Marketing & Media;Dec2015, Vol. 50 Issue 12, p12 

    The article reflects on the rules for off-label communications within pharmaceutical industries.

  • Off-label Drugs vs. the Merits of Centralised Regulatory Control. Boscheck, Ralf // Intereconomics;Sep2008, Vol. 43 Issue 5, p277 

    Escalating health care expenditures are rekindling regulatory interest in the pharmaceutical industry on both sides of the Atlantic. The focus is increasingly on off-label drug use, i.e. the use of a drug for indications different from those for which it has officially been approved –...

  • Off-label use of antibiotics in hospitalized patients: focus on tigecycline. Curcio, Daniel // Journal of Antimicrobial Chemotherapy (JAC);Dec2009, Vol. 64 Issue 6, p1344 

    The article presents a study that deals with off-label administration of antibiotics in hospitalized patients. The authors offered information on characteristics of a group of patients treated with tigecycline, a class of antibiotics named glycylcyclines active in vitro against a variety of...

  • Group urges study of drugs' off-label use. J. G. D. // Medical Marketing & Media;Jan2009, Vol. 44 Issue 1, p16 

    The article focuses on the off-label use of 14 widely prescribed medications proposed by researchers at Stanford University, the University of Illinois and the University of Chicago. The researchers notes that additional study to identify the effectiveness and safety of these medications for...

  • Jail for Off-Label Promotion?  // Pharmaceutical Representative;Jul2011, Vol. 41 Issue 7, p11 

    The article focuses on the move of federal prosecutors to seek jail time for four executives of Pennsylvania-based Synthes who have pleaded guilty to a misdemeanor involving the off-label use of a bone cement product.

  • US drug company executives could face criminal charges. Lenzer, Jeanne // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/23/2010, Vol. 341 Issue 7778, p851 

    The article reports on the possibility that the executives of drugs companies in the U.S. could face charges in a criminal court for promoting off-label drug use.

  • IPA calls for better monitoring of off-label prescribing.  // PharmacoEconomics & Outcomes News;3/17/2012, Issue 649, p4 

    The article reports on a study which found that patients prescribed an off-label medicine receive poor monitoring and surveillance in Ireland.

  • Post Caronia: Is a new paradigm needed for off-label medication usage? Rumore, Martha M // Journal of Medical Marketing;Nov2013, Vol. 13 Issue 4, p212 

    In United States v. Caronia (2012), a criminal misbranding, off-label promotion case, the Second Circuit ruled that the Food and Drug Administration’s (FDA) enforcement of pharmaceutical manufacturers violates the First Amendment. Pharmaceutical manufacturers view Caronia as a watershed...

  • Off-label prescribing in macular degeneration. McCartney, Margaret // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/22/2011, Vol. 343 Issue 7828, p826 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics